Cite
Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013;6:1481-91doi: 10.2147/OTT.S51887.
Wu, X., Liang, W., Hou, X., Lin, Z., Zhao, H., Huang, Y., Fang, W., Zhao, Y., Wu, J., Yang, Y., Xue, C., Hu, Z., Zhang, J., Zhang, J., Ma, Y., Zhou, T., Qin, T., & Zhang, L. (2013). Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and therapy, 61481-91. https://doi.org/10.2147/OTT.S51887
Wu, Xuan, et al. "Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC." OncoTargets and therapy vol. 6 (2013): 1481-91. doi: https://doi.org/10.2147/OTT.S51887
Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013. PMID: 24204163; PMCID: PMC3818102.
Copy
Download .nbib